Background/Objectives: Micronutrient deficiencies are prevalent worldwide, and a major cause of infant death. Supplementation with multiple micronutrients during pregnancy might improve micronutrient status of the newborn, thereby reducing morbidity and death. Moreover, maternal supplementation might affect the newborn's immune development. Therefore, this study investigated the effects of maternal zinc and b-carotene supplementation on the infant's morbidity and immune function during the first 6 months of life. Subjects/Methods: Mothers were supplemented during pregnancy with b-carotene and/or zinc, in addition to iron and folic acid, in a randomized, double-blind controlled trial. Newborn infants (n ¼ 136) were followed up for 6 months. Results: Infants born from mothers receiving zinc during pregnancy had significantly fewer episodes of diarrhoea than infants born from mothers not receiving zinc (0.2 and 0.4, respectively), but more episodes of cough (1.3 and 0.9 respectively) during the first 6 months. Maternal b-carotene supplementation had no effect on infants' morbidity. Cytokine production in the newborns was affected by maternal zinc and b-carotene supplementation, with zinc supplementation giving higher interleukin-6 production (16% higher), and b-carotene supplementation leading to lower interferon-g production (36% lower). Conclusions: This study shows that maternal supplementation with zinc and b-carotene affected the newborn's immune development in specific ways, but only maternal zinc supplementation significantly affected morbidity in the infants. Addition of zinc to routine iron and folic acid supplements for pregnant women could be an effective way to reduce diarrhoeal disease during the first 6 months of life, albeit at the expense of more episodes of cough.
Introduction
Micronutrient deficiency during infancy and childhood, especially deficiency of vitamin A and zinc, leads to an increased risk of morbidity and mortality from infectious diseases, and contributes to 41 million child deaths a year (Beaton et al., 1992; Sazawal et al., 1998; Black et al., 2008) . Maternal nutritional status can be an important factor determining the micronutrient status of a breastfed infant (Dijkhuizen et al., 2001 Baylin et al., 2005) . Supplementation with micronutrients during pregnancy has the advantage of addressing the needs of both mothers and infants simultaneously.
Vitamin A supplementation reduces mortality in children between 1 and 5 years by an estimated 23% (Beaton et al., 1992) . Several approaches to reduce vitamin A deficiency in children o1 year of age have been implemented, including intermittent high-dose vitamin A supplementation of infants and single high-dose vitamin A supplementation of the mother directly post-partum (WHO, 1998) , but these interventions have not been very successful in improving vitamin A status of infants (Ayah et al., 2007) . Moreover, effects of vitamin A supplementation in infants on morbidity and mortality have been disappointing (Malaba et al., 2005) . For example, a recent trial in Mexico reported a 27% increase in diarrhoeal disease episodes and a 23% increase in fever episodes in infants receiving vitamin A supplementation every 2 months, although the effect was dependent on housing conditions (Long et al., 2006) .
Zinc supplementation in children has been associated with reductions in morbidity from infectious diseases, especially diarrhoeal and respiratory infections (Bhutta et al., 2000) , and zinc supplementation during pregnancy reduced the incidence and prevalence of diarrhoeal disease in low birth weight newborns (Osendarp et al., 2001) . Surprisingly, two large trials of iron and zinc supplementation in children failed to find a significant beneficial effect of zinc supplementation on mortality in children under the age of 12 months (Sazawal et al., 2007; Tielsch et al., 2007) . Hence, although there appears to be beneficial effects in the case of supplementation with vitamin A and zinc in children above 12 months of age, evidence is less clear for infants.
Both vitamin A and zinc are known to have immunomodulating properties. Vitamin A deficiency favours the development of cellular (or Th1 cell) immune responses, whereas vitamin A supplementation appears to stimulate humoral (or Th2 cell) responses (Stephensen, 2001; Schuster et al., 2008) . Zinc deficiency leads to a general suppression of immune reactivity with lower production of cytokines of both Th1 or Th2 type being reported (Rink and Kirchner, 2000; Wieringa et al., 2004) , and supplementation with zinc restores decreased cytokine responses. The development of the human immune system begins at embryogenesis, and prenatal exposure to immune-modulating agents can have long-lasting effects throughout childhood and into adult life, as shown for example, organic toxins (Hertz-Picciotto et al., 2008) .
This study investigated the effects of supplementation during pregnancy with zinc and/or b-carotene, in addition to iron and folic acid, on morbidity of the newborn infants during the first 6 months of life and on immune responses 6 months after birth. Furthermore, the 2 Â 2 factorial design of the study allowed exploration of possible interactions between zinc and b-carotene on morbidity and immune function.
Subjects and methods

Study design and location
The study was a follow-up study of a randomized, doubleblind, controlled supplementation trial in 229 pregnant women with a gestational age o20 weeks, living in a rural area in West Java, Indonesia . All women were supplemented with iron and folic acid (30 mg of iron as ferrous fumarate and 0.4 mg of folic acid per day). In addition to iron and folic acid, one group of women received b-carotene (4.5 mg per day), one group zinc (30 mg of zinc as sulphate per day) and one group b-carotene plus zinc (4.5 and 30 mg per day, respectively). Supplements were given as capsules, and taken daily until delivery. Infants were born between November 1998 and July 1999. Infants and mothers were followed up monthly until the infants were 6 months old. Sample size calculations were primarily for micronutrient status outcomes, for which we had calculated a minimum sample size of 63 infants per group to detect a difference in retinol concentrations of 0.10 mmol/l, with an s.d. of 0.20 mmol/l. Moreover, an earlier study on cytokine production in infants receiving iron, zinc or b-carotene supplementation had shown differences of around 11 mg/l in interleukin-6 (IL-6) production (with an s.d. of 19 mg/l) and 340 ng/l of interferon-g (IFN-g) production (with an s.d. of 600 ng/l), requiring a sample size of 40 and 49 infants, respectively. The 2 Â 2 factorial design furthermore enables combining of groups in case there are no interactions between zinc and b-carotene supplementation. Finally, a sample size of 50 children per supplement (zinc or b-carotene) would allow detection of a difference of 425% in the incidence of diarrhoea, assuming that 40% or less of the children in the control group experience at least 1 episode of diarrhoea.
Subjects and procedures
The women had been informed at the beginning of supplementation, and written informed consent was given. Exclusion criteria at enrolment were twin pregnancy and congenital abnormalities. A blood sample (5 ml) was collected at the end of the study of mother and infant for assessment of micronutrient status and immune responses. Morbidity was assessed monthly with a structured recall of signs and symptoms observed by the mother during the previous weeks, and recorded per week. A similar recall used earlier in the same study area was shown to give almost identical results as a daily morbidity record obtained by village health volunteers (unpublished data). The recall focused on symptoms of fever, cough, shortness of breath, diarrhoea (43 watery stools per day) and vomiting, in accordance to local perceptions and using standard definitions and local terms.
Methods
Non-fasting, morning blood samples were collected using a closed-tube vacuum system (Becton and Dickinson, Leiden, The Netherlands). Blood samples were immediately stored at 4 1C and separated within 5 h. Plasma and serum samples were aliquoted and stored at À30 1C until analysis.
Cytokine production was measured using an ex vivo whole blood stimulation assay in 110 infants only, as blood collection was insufficient in 26 infants to perform the assay. Within 15 min, 200 ml of whole blood was diluted 1:1 with RPMI (RPMI 1640, Dutch Modification, Costar, Badhoevedorp, The Netherlands; with pyruvate, glutamin and gentamycin 1% w/v each), and incubated with either phytohaemagglutinin (Sigma, Zwijndrecht, The Netherlands) in a final concentration of 30 mg/l, lipopolysaccharide (Escherichia coli serotype 055:b5; Sigma) in a final concentration of 10 mg/l, or phosphate-buffered saline as blank control, and then incubated at 37 1C for 10 h. After incubation, the supernatant was collected for determination of cytokine concentrations. Concentrations of IL-6 were determined in the supernatant of the phytohaemagglutinin-stimulated blood, and concentrations of IFN-g in the supernatant of lipopolysaccharide-stimulated blood.
Details on the determination of micronutrient status indicators were published earlier . The cytokines IFN-g and IL-6 were measured using enzymelinked immunosorbent assay (Pelikine, CLB, Amsterdam, The Netherlands, calibrated with the standards of the National Institute of Biological Standards and Controls, Potters Bar, UK). C-reactive protein and a1-acid glycoprotein were measured using immunoturbidimetric techniques at the Northern Ireland Centre for Diet and Health, University of Ulster, Northern Ireland (Cobas Fara analyzer, Roche Products, Welwyn, UK). The coefficient of variances for the all assays were o10%.
Ethical approval
The protocol was approved by the Ethical Committees of the National Health Research and Development Centre of Indonesia and of the Royal Netherlands Academy of Arts and Sciences.
Statistical analysis
Data were checked for normal distribution using the Kolmogorov-Smirnov test of normality. Effects of supplementation on number of episodes and days with ill were analysed by ordinal logistic regression analysis, with sex (as factor) and birth weight and age of the mother (as covariates) included in the model. Duration of each episode was calculated from total days ill divided by total number of episodes for each symptom per each child. Episodes were considered distinct from each other when there was a symptom-free period of at least 7 days between them. Episodes with more than 1 symptom were considered as 1 episode, but each symptom contributed to the symptomspecific analysis. The frequencies of reports on 'shortness of breath' and 'vomiting' were too low to allow meaningful statistical analysis as separate symptoms, but were included in the total illness counts. The occurrence of the first event for an illness was analysed with Cox-regression analysis, again controlling for sex and birth weight. Cytokine concentrations were expressed as concentrations relative to those in the control group, by dividing by the mean concentration in the control group, and were analysed with analysis of covariance, controlling for the acute phase proteins C-reactive protein and a1-acid glycoprotein. If the overall F-test was significant, effects of prenatal supplementation was further explored. Main effects were considered significant if Po0.05, and interactions (such as between zinc and b-carotene supplementation) were considered significant if Po0.1. However, for all outcomes, the interaction between prenatal zinc and b-carotene supplementation was not significant (P40.2 in all cases) and therefore, effects of zinc and b-carotene supplementation are presented, and not the four group analyses. All statistical analyses were performed using SPSS (Version 14.0, SPSS Inc., Chicago, IL, USA) software.
Results
Of the 179 women who were supplemented during pregnancy until delivery, 170 were enrolled after delivery with their newborn infants for follow-up for 6 months. The infants of nine mothers were not enrolled for follow-up because of twin pregnancy (n ¼ 3), stillbirth (n ¼ 1) or neonatal death (n ¼ 5).
Newborn infants were evenly born into the four groups ( Figure 1 ) between November 1998 and July 1999. There was no significant difference in birth weight among the groups. During follow-up, 34 mother-infant pairs dropped out for various reasons ( Figure 1) ; hence, 136 mother-infant pairs completed the study. Compliance to follow-up visits was excellent, with 494% of the infants having data on five or more visits. All infants received breast feeding, although most of them no longer exclusively at 6 months of age.
At the age of 6 months, there were no significant differences in anthropometry among the groups. As reported earlier, plasma retinol concentrations were significantly higher in the women supplemented during pregnancy with b-carotene and zinc combined, whereas b-carotene concentrations were higher in all women who received b-carotene during pregnancy . Infants born from mothers receiving b-carotene and zinc combined during pregnancy also had significantly higher plasma retinol concentrations at 6 months of age. There were no differences in plasma zinc concentrations among the groups.
Overall, the number of episodes of all illnesses combined was not different among the groups, with a median number of 2 episodes of illness during the first 6 months of life (range 0-5). Of the infants, 12% (16 infants) was free of any illness during the first 6 months, whereas 29.4% (40 infants) reported 1 illness, 23.5% (32 infants) reported 2 illnesses and 13.9% (19 infants) reported 43 episodes of illness. Female infants had significantly fewer episodes of any illness than male infants (mean 1.6 and 2.3 episodes, respectively, P ¼ 0.003). Also, age of the mother was significantly and positively correlated to number of illness episodes (P ¼ 0.004). The median number of days with ill was 6 days (range 0-32 days), and not different among the groups. Again, females had significantly fewer days with illness than males (median 4.0 and 9.0 days respectively, Po0.001) during the first 6 months of life. This was not only due to fewer episodes of illness, as female infants also had significantly shorter duration of episodes than male infants, especially of diarrhoea (mean 2.6 and 5.6 days, respectively, P ¼ 0.001) and fever (mean 2.6 and 3.5 days, respectively, P ¼ 0.033).
Supplementation during pregnancy significantly affected the number of episodes with cough and diarrhoea during the first 6 months of life. Infants born from mothers who received zinc during pregnancy had significantly more episodes of cough than infants born from mothers not receiving zinc during pregnancy (1.3 and 0.9 episodes, respectively, P ¼ 0.028). In contrast, infants born from mothers receiving zinc during pregnancy had only half the number of episodes with diarrhoea as compared with infants born from mothers who did not receive zinc during pregnancy (means 0.2 and 0.4 episodes, respectively, P ¼ 0.032). This effect of prenatal zinc supplementation on diarrhoeal disease was stronger in infants with a lower birth weight. In infants with a birth weight of o ¼ 3.0 kg (n ¼ 61 infants), prenatal zinc supplementation was significantly associated with fewer episodes of diarrhoea (mean 0.1 and 0.5 diarrhoeal episodes, respectively, P ¼ 0.017), whereas in infants with a birth weight 43.0 kg (n ¼ 75), there was no significant effect of zinc supplementation during pregnancy on diarrhoeal disease (0.3 and 0.4 episodes, respectively, P40.1). A cut-off of 3.0 kg was used, as there were only 11 infants with a birth weight o2.5 kg (8% of the infants), making meaningful statistical analysis impossible. The duration of each episode for each symptom was not affected by either zinc or b-carotene supplementation.
The time of the first occurrence of illness in the newborn was also affected by supplementation during pregnancy.
Infants born from mothers receiving zinc during pregnancy had their first episode of diarrhoea significantly later than infants born from mothers not receiving zinc during pregnancy (Cox-regression, P ¼ 0.026, controlling for sex, b-carotene supplementation and birth weight, Figure 2 ). In contrast, infants born from mothers receiving zinc supplementation during pregnancy had their first episode of cough significantly earlier than infants born from mothers not receiving zinc during pregnancy (Cox regression, P ¼ 0.050, controlling for sex, b-carotene supplementation and birth weight, Figure 2 ). There was no significant effect of b-carotene on the first occurrence of cough or diarrhoea.
Prenatal supplementation also significantly affected ex vivo cytokine production of the infants at 6 months of age. Infants born from mothers receiving zinc had a significantly higher IL-6 production (40.9±14.7 and 36.6±16.5 mg/l in the zinc only (n ¼ 28) and zinc þ b-carotene group (n ¼ 24), respectively, as compared with 33.8 ± 15.3 and 33.3 ± 10.4 mg/l in the control (n ¼ 28) and b-carotene (n ¼ 30) groups). In contrast, infants born from mothers receiving b-carotene had significantly lower IFN-g production (681 ± 628 and 643±600 ng/l in the b-carotene and b-carotene þ zinc groups, respectively) as compared with infants born from mother receiving control (966 ± 939 ng/l) or zinc (1125 ± 1083 ng/l, Figure 3 ). As compared with infants born in the control group, zinc supplementation during pregnancy increased ex vivo IL-6 production at 6 months of age by 16% (P ¼ 0.042), but with no significant effect on IFN-g production ( þ 9%, P40.2). Supplementation with b-carotene during pregnancy decreased IFN-g production with 36% (P ¼ 0.030), but had no significant effect on IL-6 production (À5%, P40.2). Prenatal zinc and b-carotene and morbidity in infants FT Wieringa et al 
newborns eligible for follow-up
Discussion
This study shows that zinc supplementation during pregnancy had a distinct impact on morbidity and immune function during the first 6 months of life. There were fewer episodes of diarrhoea, with the first episode occurring later in life, in infants born from mothers receiving zinc during pregnancy. This effect was stronger in infants with lower birth weights, which has been reported before (Osendarp et al., 2001) . Infants with a lower birth weight are likely to be more at risk for functional zinc deficiency as catch-up growth requires higher zinc requirements, and hence would likely benefit more from improved maternal zinc status during pregnancy, even though this is not reflected in changes in serum zinc concentrations in mother or infant (King, 1990) . At the same time, prenatal zinc supplementation increased the number of episodes of cough. We believe that the lower incidence of diarrhoea and the higher incidence of cough are due to the same mechanism: a more reactive neonatal immune system after prenatal zinc supplementation. The higher incidence of cough after prenatal zinc supplementation does not necessarily mean more respiratory infections. It might be that prenatal zinc supplementation leads to a better immune response to respiratory infection, with more sputum production and more cough, which is noted by the mother. Illustratively, malnourished children, most of them severely zinc deficient, have been shown to have pulmonary infections without signs or symptoms (Doherty et al., 1991) .
The higher production of IL-6 in infants born from mothers receiving zinc during pregnancy might be due to a better functional zinc status in these infants. However, anthropometrical indices were not different among the groups, arguing against differences in functional zinc status at 6 months of age among the groups. Rather, we surmise that the prenatal supplementation modified the intrauterine immune development of the neonate, explaining the effects found on morbidity and immune responses at 6 months of age. Animal models have shown several distinct effects of marginal zinc deficiency in utero on the immune function of the newborn, including reduced amounts of total antibody, reduced T-cell proliferation in response to mitogen and reduced neutrophil functioning (Wellinghausen, 2001) . Interestingly, zinc supplementation of zinc-deficient pregnant rats increased IFN-g production in pups, but zinc supplementation of zinc-adequate pregnant rats decreased IFN-g production, highlighting the fine, sensitive balance between insufficient, adequate, and excessive zinc (Raqib et al., 2007) . Data on studies conducted on humans are lacking, and to our knowledge, the present study is the first to report effects on cytokine production in infants born from mothers receiving zinc or b-carotene during pregnancy. If the pregnant rat model mentioned above is representative for humans, the nonsignificant 9% higher IFN-g production in the infants born from mothers receiving zinc during pregnancy would argue for pre-existing, marginal maternal zinc deficiency. The significant reduction in number of diarrhoeal disease episodes as found in this study was also observed in a study in Bangladesh (Osendarp et al., 2001) . In contrast, a study in Peru found no effect of prenatal zinc supplementation on diarrhoeal prevalence during the first 12 months of life (Iannotti et al., 2008) . The amount of zinc supplemented (30 mg in the first two studies, 15 mg in the study in Peru), as well as the amount of iron (30 mg in this study, none in Bangladesh and 60 mg in Peru) may be important factors, which could explain these differences.
Maternal zinc supplementation during pregnancy could give effects on the immune system, which are distinctly different from those of direct supplementation of the infant.
Whether this is due to timing of the intervention in relation to critical windows in the development of the neonatal immune system in utero and after birth, to other intra-uterine maternal influences, or to differences in dosage is unknown (West, 2002) . However, understanding these differential effects is needed to guide public health interventions to effectively reduce infant morbidity and mortality globally. Recently, two large studies on zinc supplementation in infants and children failed to show a significant benefit of zinc supplementation in children under the age of 1 year on mortality (Sazawal et al., 2007; Tielsch et al., 2007) . Perhaps, maternal zinc supplementation can be more beneficial in reducing infant mortality.
Studies on effects of vitamin A supplementation on morbidity and mortality in infants have given conflicting results. In this study, despite improved vitamin A status in the infants in the b-carotene þ zinc group, there was no reduction in morbidity in this group, which corresponds with earlier studies. Moreover, other immune-modulating events such as childhood vaccinations might modulate the effects of vitamin A or b-carotene supplementation (Benn et al., 2003) . The fetal and newborn immune response is strongly biased towards Th2-cell cytokine responses. This is believed to be an evolutionary adaptation, protecting against toxic effects of Th1-cell cytokines, such as IFN-g, which might induce spontaneous abortion (Levy, 2007) . However, this Th2 skewing of the immune responses leaves the neonate vulnerable for bacterial and viral infections. Therefore, beginning directly after birth, the neonatal immune response is slowly re-calibrated towards a Th1 response, a process which most infants complete by 6 months of age (Hertz-Picciotto et al., 2008) . Interestingly, earlier maturation of the Th1-cell responses has been associated with protection against allergy and atopic diseases and infections (Levy, 2007) . In this study, the 36% reduction in IFN-g production after prenatal b-carotene supplementation warrants further research, as this prolonged bias towards Th2-cell responses might not only make the infant more susceptible to microbial infections, but might also predispose to allergy and asthma later in life (Wieringa et al., 2008) . Earlier, we reported lower IFN-g production in infants receiving b-carotene supplementation or zinc supplementation (Wieringa et al., 2003) . In this study, only maternal b-carotene supplementation, and not maternal zinc supplementation affected IFN-g production.
This study has several limitations, which include the monthly morbidity recall, and the relatively small sample size. From the 136 infants who finished the follow-up, cytokine data were available only for 110 of them (81%). This was due to difficulties in obtaining enough venous blood from the infants for the ex vivo incubation and due to the fact that sterile conditions were not always met in the field. For none of the outcomes was there a significant interaction between prenatal b-carotene supplementation and prenatal zinc supplementation, indicating that effects of both nutrients are independent of each other. Ex vivo production of IL-6 and IFN-g in infants at 6 months of age, born from mothers supplemented during pregnancy with b-carotene and/or zinc, in addition to iron and folic acid, relative to control group. Bars represent 95% confidence interval.
